Pay in 4 interest-free payments of $6.32 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Follow-up Patients were followed from the index date (the date of GLP-1 receptor agonist prescription) until death, loss to follow-up, or the end of the study period (December 1, 2025), whichever occurred first
Alshiekh-Nasany R et al
The kicker
Conclusions This analysis demonstrates that semaglutide 2.4 mg represents a cost-effective intervention for obese patients with MASH (F3) without diabetes within the Italian healthcare setting, generating substantial health gains and remaining below the commonly accepted willingness-to-pay threshold, reporting an ICER equal to 22,691 per QALY gained for the basecase scenario
US$ 28.54
US$ 20.19
US$ 28.44
US$ 20.49
